Boehringer Ingelheim, Lilly (LLY) Announce Phase III for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes Met Primary Endpoint

Boehringer Ingelheim and Eli Lilly and Company today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their prim https://www.streetinsider.com/Corporate+News/Boehringer+Ingelheim%2C+Lilly+%28LLY%29+Announce+Phase+III+for+Empagliflozin+as+Adjunct+to+Insulin+in+Type+1+Diabetes+Met+Primary+Endpoint/14338091.html